The Prostate Specific Antigen (PSA) test, developed at Roswell Park over 25 years ago, continues to be the best available test for prostate cancer, and an aid to early diagnosis and treatment monitoring. But thanks to your gifts, Roswell Park scientists are looking at the PSA and other biomarkers in entirely new ways to help the more than 219,000 men diagnosed with prostate cancer each year across our country.
Recent research by Kailash Chadha, PhD, Department of Molecular and Cellular Biology, is identifying serum biomarkers in the blood that are more sensitive and specific than PSA and that, either independently or in conjunction with PSA, will allow for more accurate diagnosis and management of clinically relevant prostate cancer.
Dr. Chadha’s donor-funded research also studied how the prostate specific antigen might become a molecular target for therapies to inhibit angiogenesis (the repair and growth of blood vessels) in tumors. This approach offers the potential for saving lives through less toxic and invasive cancer treatments.